Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Litigation resolved with prejudice through mutual releases and no monetary payment by either party.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Litigation resolved with prejudice through mutual releases and no monetary payment by either party
- Onvansertib license retained, with updated exclusivity restricting Nerviano from competing during the royalty term
- New annual sales-based license fee and Phase 3 development milestone obligations increase future cash commitments
- Assignment provisions may require Cardiff to share transaction proceeds based on Phase 3 timing
- Nerviano gains board observer and Scientific Advisory Board seats, increasing governance involvement
Item 7.01 · Regulation FD Disclosure
- Section 18 Exchange Act liability disclaimer for the disclosed information
- Information excluded from automatic incorporation into future Securities Act or Exchange Act filings
Item EX-99.1 · Exhibit EX-99.1
- Settlement resolves all disputes over global onvansertib rights under the 2017 exclusive license agreement
- Cardiff and NMS agreed to mutually release litigation claims and seek dismissal with prejudice
- Expanded royalty terms and Cardiff development objectives clarify obligations for the upcoming Phase 3 program
- NMS gains rights to appoint a Board observer and join Cardiff’s Scientific Advisory Board
- Agreement supports planned global Phase 3 development in first-line RAS-mutated metastatic colorectal cancer
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.